Ahmed Zaghloul – CEO, October Pharma, Egypt
Ahmed Zaghloul, CEO of October Pharma, stresses the need for better infrastructure for biosimilars in Egypt to stay competitive on a global level. He also highlights October Pharma’s ambitious export…
October Pharma (OP) S.A.E is an Egyptian enterprise molded by global aspirations. This has always demanded a preparedness and long- term organizational vision that can encompass the turbulence’s and paradoxes of shifting terms and terrain’s of business.
October Pharma (OP) is producing different pharmaceutical dosage forms of products under cGMP rules & regulations:
Solid (tablets, capsules & powder)
Liquid (syrup, drops, solution & spay)
Subcontract (Toll Out Manufacturing) for:
Soft Gelatin Capsules
Ampoule & Vial
Cream & Suppository
Powder
Contact
Piece #190, St. #25, 1st industrial zone,
6 October city. Cairo, Egypt
Tel: 38201832 / 38201652 / 38201329
Fax: +02 38201653
Email: info@octoberpharma.com
Ahmed Zaghloul, CEO of October Pharma, stresses the need for better infrastructure for biosimilars in Egypt to stay competitive on a global level. He also highlights October Pharma’s ambitious export…
“My primary concern is not the current economic situation, but rather the fact that there does not appear to be a clear vision for how Egypt can overcome these challenges…
Dr. Rostom, Deputy Head of the pharmaceutical chamber of the Federation of Egyptian Industries explains Egypt’s unique potential for investors and discusses key issues to be addressed in order to…
The President and the Counselor of the French Chamber of Commerce and Industry in Egypt, discuss plans to establish a French industrial zone in Alexandria (North of Egypt) to further…
Egypt is back in business, with economic growth and investor confidence in Egypt nearly back to levels seen in 2010, GDP growth up to four percent, and several high profile…
His Excellency, Professor Dr. Hatem El Gabaly, the minister of health and population of Egypt, shows no doubt that the strong and necessary reform his government is currently undertaking…
See our Cookie Privacy Policy Here
